Condition (MeSH)
Hyperoxaluria
ClinicalTrials.gov lists 68 trials for Hyperoxaluria or a narrower condition beneath it. Allena Pharmaceuticals has the most among industry and government lead sponsors, with 7.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 more section with rows
48 of the 68 trials are tagged with Hyperoxaluria itself; the rest are tagged with a narrower condition beneath it.
When did Hyperoxaluria trials start? (21)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 6 |
| 2023 | 1 |
| 2022 | 3 |
| 2021 | 3 |
| 2020 | 3 |
| 2019 | 8 |
| 2018 | 6 |
| 2017 | 3 |
Showing 10 of 21 earlier years.
No forecast is made for this condition: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 20 months across 48 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hyperoxaluria trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 7 |
| Phase 2 | 12 |
| Phase 2/3 | 2 |
| Phase 3 | 11 |
| Phase 4 | 2 |
| Not applicable | 7 |
| Observational | 20 |
| Expanded access | 1 |
How many Hyperoxaluria trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 10 |
| Active, not recruiting | 1 |
| Completed | 42 |
| Approved for marketing | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hyperoxaluria trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Allena Pharmaceuticals | 7 |
| Alnylam Pharmaceuticals | 6 |
| Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 6 |
| OxThera | 6 |
| Biocodex | 2 |
Showing 5 of 9 sponsors.
Which drugs are being tested for Hyperoxaluria? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Lumasiran | 6 |
| Nedosiran | 5 |
| ALLN-177 | 5 |
| Oxalobacter formigenes | 3 |
| Stiripentol | 2 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| YOLT-203 | 2 |
| Oxabact OC5 capsules | 1 |
| Urine samples collect | 1 |
| Test meal | 1 |
| ALLN-177 low dose | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hyperoxaluria trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Nephrolithiasis | 11 | 6 |
| Abdominal pain | 4 | 3 |
| Renal colic | 4 | 3 |
| Ureterolithiasis | 4 | 2 |
| Device related infection | 3 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Hyperoxaluria? (26)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial. | American journal of kidney diseases : the official journal of the National Kidney Foundation | 2023 | Yes |
| PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. | Kidney international | 2023 | Yes |
| Randomized Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria. | NEJM evidence | 2022 | Yes |
| [Nephrocalcinosis in children]. | Nephrologie & therapeutique | 2021 | Yes |
| ALLN-177, oral enzyme therapy for hyperoxaluria. | International urology and nephrology | 2019 | Yes |
Showing 5 of 26 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.